Dyne Therapeutics, Inc. Common Stock (DYN) is a publicly traded Healthcare sector company. As of May 20, 2026, DYN trades at $16.57 with a market cap of $2.73B and a P/E ratio of -4.65. DYN moved +4.59% today. Year to date, DYN is -13.95%; over the trailing twelve months it is +36.54%. Its 52-week range spans $6.36 to $36.09. Analyst consensus is strong buy with an average price target of $35.31. Rallies surfaces DYN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Dyne Therapeutics Launches 72-Week Phase 3 FORZETTO Trial in 90 Duchenne Muscular Dystrophy Patients: Dyne Therapeutics has begun its global 72-week Phase 3 FORZETTO trial enrolling approximately 90 Duchenne muscular dystrophy patients amenable to exon 51 skipping, with primary endpoint change in rise-from-floor velocity at Week 73. The trial, designed to support a BLA for U.S. accelerated approval, aligns with FDA guidance.
| Metric | Value |
|---|---|
| Price | $16.57 |
| Market Cap | $2.73B |
| P/E Ratio | -4.65 |
| EPS | $-3.47 |
| Dividend Yield | 0.00% |
| 52-Week High | $36.09 |
| 52-Week Low | $6.36 |
| Volume | 362.68K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-446.21M |
| Gross Margin | 0.00% |
11 analysts cover DYN: 0 strong buy, 9 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $35.31.